Dr. Reddy’s generic twice-yearly lenacapavir received FDA tentative approval for HIV PrEP. It is expected to cost $40 a year in 120 llow- and middle-income countries (LMICs), with first supplies due by the end of 2026.
|Articles|November 30, 2021
The Latest on Omicron
Author(s)John Parkinson
As there is a lot of information regarding the Omicron variant, here is our latest slideshow to offer some insights on it.
Advertisement
On Thanksgiving, both public health officials from South Africa and the United Kingdom gave press conferences discussing what they had learned about the new COVID-19 variant.
By the next day, the World Health Organization (WHO) had renamed it the Omicron variant, and has been giving updates on information they have obtained.
Here in the United States, President Joe Biden and his administration have been working towards reducing travel from the African countries that are thus far affected by the Omicron.
Moderna has already said it will
There is still a lot to be learned about the new variant and information is quickly being disseminated to the public to help clinicians and the general public understand what is going on.
Although there is still a lot to be learned, check out our latest slideshow to find out the latest developments.
Advertisement
Related to this article
David Altarac, MD, discusses 2025 SENTRY data, ESBL considerations in empiric therapy, and where ceftobiprole fits alongside ceftaroline in S aureus bacteremia.
A Yakima County resident exposed to infected dairy cattle has died of avian influenza. A third human case has also been confirmed as H5N1 spreads to 33 herds in the county.
Jean van Wyk, MBChB, MFPM, discussed the 5-year OPERA data from IDWeek 2026 as well as the anticipated CROWN study results.
Voceryq earned FDA accelerated approval for adults with RRP after 7 of 26 patients (27%) needed no surgery for 12 months in RRP-001; a confirmatory trial is required.
Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.
In a national survey of 959 US adults, 27.9% said they had exaggerated or made up symptoms to obtain antibiotics, most often cold-like symptoms, with implications for outpatient stewardship.
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Advertisement
Advertisement
Trending on Contagion Live
1
Washington State Reports First US Avian Influenza Death of 2026
2
FDA Tentatively Approves First Generic Lenacapavir PrEP for 120 LMICs
3
FDA Approves Voceryq, First Plasmid DNA Immunotherapy for Recurrent Respiratory Papillomatosis
4
Cefiderocol Activity Improves in Physiologic Media, Synergizes With LL-37
5